Stephani Christensen, MD
Hematology & Oncology · Henderson, NVNPI 1285869727
Payments from drug & device makers
What this record shows
The money is spread across several categories — consulting fees (46.5%), food and beverage and speaking fees — rather than concentrated in one kind of arrangement. Daiichi Sankyo Inc. accounts for 62.7% of it on its own, with 21 other manufacturers making up the rest. Reporting peaked in 2019 at $5,924 and has fallen 72.5% since, to $1,627 in 2025. That places this record below the midpoint for hematology & oncology clinicians in NV, where the typical reported total is $9,657.
Across 126 payments — averaging $80.28 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Daiichi Sankyo Inc.$6K
- Pfizer$2K
- Novartis$1K
- Boston Scientific$199
- AstraZeneca$172
- Novocure Inc.$163
- plus $457 from 16 others
Across 88 payments — averaging $55,787 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Novartis$4.4M
- Merck$204K
- Eli Lilly$126K
- Seagen Inc.$94K
- Pfizer$28K
- AstraZeneca$28K
- plus $26K from 2 others
What the payments were for
- Consulting fees$4,70046%
- Speaking & faculty fees$1,45014%
- Travel & lodging$7467%
- Food & beverage$2,00420%
- Education$3183%
- Other$8979%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Daiichi Sankyo Inc. | 59 | $6,343 |
| Pfizer | 13 | $1,594 |
| Novartis | 19 | $1,188 |
| Boston Scientific | 4 | $199 |
| AstraZeneca | 7 | $172 |
| Novocure Inc. | 2 | $163 |
| Amgen | 1 | $71 |
| Beigene USA, Inc. | 2 | $46 |
| Sobi, Inc | 1 | $37 |
| Gilead | 2 | $37 |
| Johnson & Johnson(2 entities) | 2 | $34 |
| Beone Medicines USA, Inc. | 1 | $29 |
| Array Biopharma Inc | 4 | $25 |
| Bristol Myers Squibb | 1 | $24 |
| Genentech USA, Inc. | 1 | $24 |
| Regeneron Healthcare Solutions, Inc. | 1 | $23 |
| GSK | 1 | $22 |
| Bayer | 1 | $21 |
| Astellas Pharma US Inc | 1 | $20 |
| E.r. Squibb & Sons, L.L.C. | 1 | $17 |
| Lilly USA, LLC | 1 | $15 |
| Merck | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$10,116 in reported general payments places this provider in the 50th percentile of 82 hematology & oncology providers in Nevada.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| KisqaliRibociclib Succinate | 19 | $295,284 |
| TagrissoOsimertinib Mesylate | 12 | $198,856 |
| XtandiEnzalutamide | 13 | $191,209 |
| IbrancePalbociclib | 13 | $142,610 |
| EliquisApixaban | 78 | $52,179 |
| XareltoRivaroxaban | 24 | $35,559 |
| Anastrozole | 417 | $8,557 |
| Exemestane | 30 | $2,995 |
| Tamoxifen Citrate | 94 | $2,005 |
| Letrozole | 112 | $1,982 |
| Hydroxyurea | 15 | $924 |
| Gabapentin | 56 | $779 |
| Prochlorperazine Maleate | 21 | $634 |
| Venlafaxine Hcl ErVenlafaxine Hcl | 19 | $561 |
| Ibandronate Sodium | 16 | $529 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| NovartisKisqali | $1,188 | $295,28419 claims |
| AstraZenecaTagrisso | $172 | $198,85612 claims |
| PfizerIbrance, Eliquis | $1,594 | $194,78991 claims |
| Astellas Pharma US IncXtandi | $20 | $191,20913 claims |
| Johnson & JohnsonXarelto | $34 | $35,55924 claims |
| Lilly USA, LLCOlanzapine | $15 | $29644 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 50th percentile of 82 hematology & oncology providers in Nevada.
Other hematology & oncology in Henderson
- Anthony NguyenHenderson$210K
- Russell GollardHenderson$105K
- Rupesh ParikhHenderson$67K
- Ramalingam RatnasabapathyHenderson$25K
- Resty TibayanHenderson$10K
- Nutan ParikhHenderson$10K
- Muhammad GhaniHenderson$9K
- Khoi DaoHenderson$8K
- Gilbert NyamuswaHenderson$4K
- Nicholas VogelzangLas Vegas$397K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.